H1

H1 Connect helps healthcare professionals find & participate in humanitarian aid work around the world by working closely with our leading NGO partners to identify opportunities. If you’re interested in joining our growing network of more than 6,000 HCPs and gain access to medical deployment opportunities, sign up here today: https://hubs.la/Q02MV2Ll0

#MSLS kicks off next week! If you're attending, we'd love to catch up with you in booth 9 and find out how we can support your needs for #KOLmapping, measuring impact, and whatever else you'd like to discuss. Don't miss our breakout session on Wednesday afternoon. Christine Medeiros and Robert Consalvo have a powerful presentation to share. See you in next week! https://lnkd.in/gdtHbKx #MSL #MSLS #MedicalAffairs #MSLSociety #12thAnnualMSLSConference

Empower your MSLs with comprehensive #HCPinsights. Kristin Cova, PharmD, and Christine Medeiros discuss strategies for optimizing #HCPengagement through digital tools. Discover how H1's detailed insights on HCP research interests, publications, and clinical activities enable MSLs to quickly tailor their communications to each HCP's latest focus for better connections. Watch now! https://hubs.ly/Q02M2jkY0 #medicalaffairs #msls #hcpdata #hcpinsights

Johnson & Johnson’s new FDA approval of its regimen to treat #lungcancer has launched it into a strong competitive position against the leading drug. In the phase 3 trial, J&J’s drug combination reduced the risk of disease progression or death by 30% compared with the leading drug as first-line treatments for EGFR-mutant non-small cell lung cancer. Patients who took the combo lived a median 23.7 months without progression, versus 16.6 months for the leading treatment. Learn more: https://hubs.la/Q02MlnJB0

In the face of ongoing medical challenges in Ukraine, H1 and Global Response Medicine (GRM) are stepping up to make a difference. By collaborating with H1, GRM efficiently recruited and deployed top-tier surgeons to support humanitarian efforts in the region. Our CEO Ariel Katz's conversation with Liza Laws at Outsourcing-Pharma provides valuable insights into this impactful partnership. Check out the interview to see how our H1 Connect platform links doctors with global missions to drive positive change: https://hubs.la/Q02MlmSk0 #HumanitarianEfforts #GlobalResponseMedicine #MedicalAid #H1Connect #UkraineAid

A top 10 pharma company recently engaged H1 to identify thought leaders in obstructive sleep apnea. Together, the medical team and H1 were able to discover relevant experts and prepare for an early launch. How did they accomplish this? Check out the full case study and learn how this pharma company was able to leverage H1 for success! https://hubs.la/Q02Mc2V10 #obstructivesleepapnea #osa #kols #hcpengagement #hcpdiscovery

Curious how a top leader in field medical strategy is helping her team make more impactful interactions with #HCPs? Kristin Cova, PharmD, Director of Medical Science Liaisons at Ferring Pharmaceuticals, shares how she leverages H1 to drive enhanced #HCPengagement. From pre-call planning to territory management, discover how Kristin uses digital tools to maximize efficiency and foster meaningful scientific dialogue with HCPs. See more here: https://hubs.la/Q02M1xhV0

At H1, we’re proud of the ways we work alongside top life sciences companies to create meaningful change in healthcare and to improve patient lives. See how our data insights have helped transform the way medical and clinical teams work – with a broader and deeper understanding of the healthcare landscape. Learn more: https://hubs.la/Q02LXYDt0

Unlock the key to effective HCP engagement. In an exclusive interview, Kristin Cova, PharmD from Ferring Pharmaceuticals discusses with Christine Medeiros how to amplify your #HCPengagement strategy and find the most influential #HCPs for impactful scientific exchange using H1. Watch now to learn how H1 is boosting #MSL impact in the field. https://hubs.ly/Q02LyPlc0 #hcps #scientificexchange #msls #ferring #ferringpharmaceuticals

Ascendis Pharma is celebrating a long-awaited FDA approval of their hormone replacement therapy to treat #hypoparathyroidism. After unanticipated delays have pushed the timeline back more than a year, the company is thrilled to finally be moving closer to launch. Hypoparathyroidism affects more 70,000+ patients in the U.S. and can lead to kidney complications and cognitive impairment. Ascendis’ therapy allowed 95% of patients to be freed from conventional therapy in a phase 3 trial. We’re happy to know patients will soon have this new treatment option available to them! https://hubs.la/Q02KZQyH0